Prostate cancer, deadly though sometimes slow-moving, gets far more press, but benign prostatic hyperplasia - enlargement (usually associated with age) of the male gland that contributes alkalinity to sperm fluid, letting the reproductive tadpoles swim longer - represented a $3.7 billion market last year. And plenty of players are on the case. Read More
